概括
神经科医生现在可以使用脑脊液 (CSF) 和血生物标志物用于痴呆症诊断和治疗决策. 新兴的血液测试可以改善阿尔茨海默病的诊断,并可能很快监测治疗的有效性.
科学领域:
- 神经学 神经学
- 生物标志物研究 生物标志物研究
- 神经退行性疾病 神经退行性疾病
背景情况:
- 大脑脊髓液 (CSF) 生物标志物用于诊断阿尔茨海默病,莱维体痴呆症和克鲁茨菲尔特-雅各布病.
- 最近FDA对阿尔茨海默病单克隆抗体治疗的批准需要准确的生物标志物确认.
- 新兴的基于血液的生物标志物正在迅速发展,用于痴呆症诊断和治疗监测.
研究的目的:
- 让神经学家熟悉目前用于痴呆症诊断的CSF和血生物标志物.
- 以生物标志物确认的诊断为基础,为治疗决策提供信息.
- 要突出痴呆症诊断和治疗监测的不断变化的景观.
主要方法:
- 对阿尔茨海默病,莱维体痴呆症和克鲁茨菲尔德特-雅各布病的已确立的CSF生物标志物的审查.
- 对新出现的基于血液的痴呆症诊断生物标志物的分析.
- 讨论生物标志物在指导治疗决策和监测治疗疗效方面的作用.
主要成果:
- 对于特定的痴呆症,CSF生物标志物已经得到了很好的确立.
- 基于血液的生物标志物显示出对诊断的敏感性和特异性的改善.
- 一种针对聚合α-synuclein的新型CSF测定有助于诊断Lewy体痴呆症.
结论:
- 生物标志物对于准确的痴呆症诊断和个性化治疗越来越重要.
- 基于血液的生物标志物对于监测治疗疗效至关重要,解决尚未满足的需求.
- 对液体生物标志物的持续研究将促进痴呆症的护理和管理.
更多相关视频
相关概念视频
01:30Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
01:26Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
57
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
57